Price movement over the last 24 hours
AbbVie Inc vs Fiverr International Ltd — how do they compare? AbbVie Inc trades at $252.57 (market cap $449.91B), while Fiverr International Ltd trades at $10.86 (market cap $403.37M). The key difference: AbbVie Inc is far larger — about 1115.4× Fiverr International Ltd's market cap, and AbbVie Inc pays a 2.72% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| ABBV | FVRR | |
|---|---|---|
Market Cap | $449.91B | $403.37M |
Sector | Health | Industrials |
52-Week High | $261.07 | $27.77 |
52-Week Low | $184.85 | $9.62 |
Enterprise Value | $513.38B | $133.97M |
Dividend Yield | 2.72% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Fiverr International (FVRR) trades at $11.22, up 3.79% today, showing signs of recovery from recent lows. The stock appears fundamentally undervalued with a P/E of 14.44 and P/S of 0.96, while revenue growth has been steady from $337M in 2022 to $431M in 2025. Recent earnings show mixed results with Q1 2026 missing expectations, but technical indicators suggest bullish momentum with strong moving average support.
FVRR presents a contrarian opportunity with attractive valuation metrics and improving profitability, though investor sentiment remains cautious due to active buyer declines and ongoing legal investigations. The company's strategy shift and strong gross margins of 81.86% provide upside potential, but competitive pressures and execution risks require careful monitoring.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →